[{"bbox": [90, 98, 369, 131], "category": "Page-header", "text": "Q-Line Biotech Limited"}, {"bbox": [90, 164, 1558, 414], "category": "Table", "text": "<table><tr><td>Net Liability</td><td>292.90</td><td>208.30</td><td>184.64</td></tr><tr><td colspan=\"4\">2. The amounts recognized in the Profit & Loss A/c are as follows:</td></tr><tr><td>Current Service Cost</td><td>53.17</td><td>39.68</td><td>36.41</td></tr><tr><td>Interest on Defined Benefit Obligation</td><td>14.06</td><td>13.11</td><td>12.71</td></tr><tr><td>Expected Return on Plan Assets</td><td></td><td></td><td></td></tr><tr><td>Net actuarial losses (gains) recognised in the year</td><td>34.85</td><td>(22.05)</td><td>(32.64)</td></tr><tr><td>Total, Included in \"Salaries, Allowances & Welfare\"</td><td>102.08</td><td>30.74</td><td>16.48</td></tr></table>"}, {"bbox": [90, 442, 1558, 1147], "category": "Table", "text": "<table><tr><td colspan=\"4\">3. Changes in the present value of defined benefit obligation:</td></tr><tr><td>Defined benefit obligation as at the beginning of the year/period Net of Fair Value of Opening Plan Assets</td><td>208.30</td><td>184.64</td><td>171.74</td></tr><tr><td>Service cost</td><td>53.17</td><td>39.68</td><td>36.41</td></tr><tr><td>Interest cost</td><td>14.06</td><td>13.11</td><td>12.71</td></tr><tr><td>Expected Return on Plan Assets</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Net actuarial losses (gains) recognised in the year</td><td>34.35</td><td>(22.05)</td><td>(32.64)</td></tr><tr><td>Benefit paid by the Company</td><td>(16.98)</td><td>(7.08)</td><td>(3.58)</td></tr><tr><td>Defined benefit obligation as at the end of the year/period</td><td>292.90</td><td>208.30</td><td>184.64</td></tr><tr><td>Current</td><td>31.08</td><td>22.47</td><td>18.83</td></tr><tr><td>Non Current</td><td>261.82</td><td>185.83</td><td>165.81</td></tr><tr><td>Total</td><td>292.90</td><td>208.30</td><td>184.64</td></tr><tr><td colspan=\"4\">Benefit Description</td></tr><tr><td>Benefit type:</td><td colspan=\"3\">Gratuity Valuation as per Act 1972</td></tr><tr><td>Retirement Age:</td><td>60 years</td><td>60 years</td><td>60 years</td></tr><tr><td>Vesting Period:</td><td>5 years</td><td>5 years</td><td>5 years</td></tr><tr><td colspan=\"4\">The principal actuarial assumptions for the above are:</td></tr><tr><td>Future Salary Rise:</td><td>7.00%P.A</td><td>7.00%P.A</td><td>7.00%P.A</td></tr><tr><td>Discount rate per annum:</td><td>6.75%P.A</td><td>7.10%P.A</td><td>7.40%P.A</td></tr><tr><td>Withdrawal Rate:</td><td colspan=\"3\">1%-5% depending on age</td></tr><tr><td>Mortality Rate:</td><td colspan=\"3\">Mortality (2012-2014)Ultimate</td></tr></table>"}, {"bbox": [90, 1179, 530, 1211], "category": "Section-header", "text": "## (B) Defined Contribution Plan:-"}, {"bbox": [90, 1243, 1555, 1372], "category": "Text", "text": "Amount of Rs. 61.80 Lakhs in 31st March 2025, Rs.48.80 Lakhs in 31 March 2024 and Rs. 37.85 Lakhs in 31 March 2023 related to contribution to Employees' Provident Fund and Amount of Rs. 1.71 Lakhs in 31st March 2025, Rs.1.92 Lakhs in 31 March 2024 and Rs.2.74 Lakhs in 31 March 2023 related to contribution to Employees' ESIC recognised as an expense and included in employee benefits expense in the Standalone Statement of Profit and Loss."}, {"bbox": [90, 1404, 600, 1435], "category": "Section-header", "text": "## 11. Additional regulatory information"}, {"bbox": [90, 1437, 749, 1467], "category": "Section-header", "text": "### a. Compliance with approved scheme of arrangements"}, {"bbox": [90, 1469, 727, 1500], "category": "Text", "text": "Company is not engaged in any scheme of arrangements."}, {"bbox": [90, 1531, 715, 1562], "category": "Section-header", "text": "### b. Compliance with numbers of layers of companies"}, {"bbox": [90, 1564, 1558, 1627], "category": "Text", "text": "The Company is in compliance with the number of layers of companies in accordance with clause 87 of Section 2 of the Act read with the Companies (Restriction on number of Layers) Rules, 2017 for the year ended March 31, 2025, 2024 & 2023."}, {"bbox": [90, 1659, 481, 1688], "category": "Section-header", "text": "### c. Utilisation of borrowed funds"}, {"bbox": [90, 1691, 1558, 1787], "category": "Text", "text": "1. During the year ended March 31, 2025, 2024 & 2023, the Company has not advanced or Loans or invested funds (either borrowed funds or share premium or kind of funds) to any other person(s) or entity(ies), including foreign entities (Intermediaries) with the understanding (whether recorded in writing or otherwise) that the Intermediary shall:"}, {"bbox": [90, 1818, 1558, 1882], "category": "Text", "text": "i) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Company (Ultimate Beneficiaries) or"}, {"bbox": [90, 1914, 1084, 1947], "category": "Text", "text": "ii) provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries."}, {"bbox": [90, 1979, 1558, 2075], "category": "Text", "text": "2. During the year ended March 31, 2025, 2024 & 2023, the Company has not received any fund from any person(s) or entity(ies), including foreign entities (Funding Party) with the understanding (whether recorded in writing or otherwise) that the Company shall:"}, {"bbox": [90, 2107, 407, 2138], "category": "Section-header", "text": "### d. Non-adjustment Items:"}]